Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: Its potential use in the treatment of bladder cancers

Pharmacology and Therapeutics

Volumn 145, Issue , 2015, Pages 1-18

  Houédé, Nadine ^a   Pourquier, Philippe ^b  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

Author keywords

AKT; PI3K; PTEN mTOR; TSC1; Urothelial bladder cancer

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 AMINO 8 [4 (2 HYDROXYETHOXY)CYCLOHEXYL] 6 (6 METHOXY 3 PYRIDINYL) 4 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 5 [5 (4 FLUORO 2 HYDROXYPHENYL)FURFURYLIDENE] 2,4 THIAZOLIDINEDIONE; ALPELISIB; APITOLISIB; BUPARLISIB; COPANLISIB; EVEROLIMUS; GEDATOLISIB; IDELALISIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OMIPALISIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PILARALISIB; PROTEIN; PROTEIN KINASE B; TASELISIB; TRICIRIBINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; V AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 1; WORTMANNIN; XL 765; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; TARGET OF RAPAMYCIN KINASE;

AKT1 GENE; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; GENE; GENE MUTATION; HUMAN; LKB1 GENE; OVERALL SURVIVAL; PIK3CA GENE; PIK3R1 GENE; PROGRESSION FREE SURVIVAL; PTEN GENE; RHEB GENE; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; TSC1 GENE; TSC2 GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; URINARY BLADDER NEOPLASMS;

ANIMALS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES; URINARY BLADDER NEOPLASMS;

EID: 84918839180     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2014.06.004     Document Type: Review

References (226)

1. E. Agarwal, A. Chaudhuri, P.D. Leiphrakpam, K.L. Haferbier, M.G. Brattain, and S. Chowdhury Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer BMC Cancer 14 2014 1471 2407
2. D.R. Alessi, S.R. James, C.P. Downes, A.B. Holmes, P.R. Gaffney, and C.B. Reese Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha Curr Biol 7 1997 261 269
3. H. Asahina, H. Nokihara, N. Yamamoto, Y. Yamada, Y. Tamura, and K. Honda Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study Investig New Drugs 31 2013 677 684
4. J.M. Askham, F. Platt, P.A. Chambers, H. Snowden, C.F. Taylor, and M.A. Knowles AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K Oncogene 29 2010 150 155
5. J.S. Aveyard, A. Skilleter, T. Habuchi, and M.A. Knowles Somatic mutation of PTEN in bladder carcinoma Br J Cancer 80 1999 904 908
6. E.B. Avritscher, C.D. Cooksley, H.B. Grossman, A.L. Sabichi, L. Hamblin, and C.P. Dinney Clinical model of lifetime cost of treating bladder cancer and associated complications Urology 68 2006 549 553 (Epub Sep 2018)
7. M. Babjuk, M. Burger, R. Zigeuner, S.F. Shariat, B.W. van Rhijn, and E. Comperat EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013 Eur Urol 64 2013 639 653
8. R.M. Bambury, and J.E. Rosenberg Actionable mutations in muscle-invasive bladder cancer Curr Opin Urol 23 2013 472 478
9. A. Bamias, I. Tiliakos, M.D. Karali, and M.A. Dimopoulos Systemic chemotherapy in inoperable or metastatic bladder cancer Ann Oncol 17 2006 553 561 (Epub Nov 2022)
10. C. Bartholomeusz, and A.M. Gonzalez-Angulo Targeting the PI3K signaling pathway in cancer therapy Expert Opin Ther Targets 16 2012 121 130
11. P. Baumann, S. Mandl-Weber, F. Oduncu, and R. Schmidmaier The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma Exp Cell Res 315 2009 485 497 10.1016/j.yexcr.2008.1011.1007 (Epub Nov 1027)
12. M.N. Becker, K.J. Wu, L.A. Marlow, P.A. Kreinest, C.A. Vonroemeling, and J.A. Copland The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro Urol Oncol 2013 2013 00251 00252
13. J. Bellmunt, R. Fougeray, J.E. Rosenberg, H. von der Maase, F.A. Schutz, and Y. Salhi Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy Ann Oncol 24 2013 1466 1472
14. D. Benjamin, M. Colombi, C. Moroni, and M.N. Hall Rapamycin passes the torch: a new generation of mTOR inhibitors Nat Rev Drug Discov 10 2011 868 880
15. J.S. Bertram, and A.W. Craig Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response Eur J Cancer 8 1972 587 594
16. S.V. Bhagwat, P.C. Gokhale, A.P. Crew, A. Cooke, Y. Yao, and C. Mantis Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin Mol Cancer Ther 10 2011 1394 1406
17. R.L. Bitting, and A.J. Armstrong Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer Endocr Relat Cancer 20 2013 12 0394
18. P.C. Black, G.A. Brown, and C.P. Dinney The impact of variant histology on the outcome of bladder cancer treated with curative intent Urol Oncol 27 2009 3 7 10.1016/j.urolonc.2007.1007.1010 (Epub Jan 1014)
19. A.M. Bogusz, D.R. Brickley, T. Pew, and S.D. Conzen A novel N-terminal hydrophobic motif mediates constitutive degradation of serum- and glucocorticoid-induced kinase-1 by the ubiquitin-proteasome pathway FEBS J 273 2006 2913 2928
20. L. Booth, N. Cruickshanks, T. Ridder, C.S. Chen, S. Grant, and P. Dent OSU-03012 interacts with lapatinib to kill brain cancer cells Cancer Biol Ther 13 2012 1501 1511
21. D.W. Bowles, W.W. Ma, N. Senzer, J.R. Brahmer, A.A. Adjei, and M. Davies A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours Br J Cancer 109 2013 1085 1092
22. S. Brachmann, C. Fritsch, S.M. Maira, and C. Garcia-Echeverria PI3K and mTOR inhibitors: a new generation of targeted anticancer agents Curr Opin Cell Biol 21 2009 194 198 10.1016/j.ceb.2008.1012.1011 (Epub Feb 1017)
23. C.D. Britten, A.A. Adjei, R. Millham, B.E. Houk, G. Borzillo, and K. Pierce Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer Investig New Drugs 2014 2014 7
24. M. Burger, J.W. Catto, G. Dalbagni, H.B. Grossman, H. Herr, and P. Karakiewicz Epidemiology and risk factors of urothelial bladder cancer Eur Urol 63 2013 234 241
25. H. Burris, J. Rodon, S. Sharma, R.S. Herbst, J. Tabernero, and J.R. Infante First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors J Clin Oncol 28 2010 (Suppl.; abstr 3005)
26. H.A. Burris III Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway Cancer Chemother Pharmacol 71 2013 829 842
27. P. Cairns, E. Evron, K. Okami, N. Halachmi, M. Esteller, and J.G. Herman Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers Oncogene 16 1998 3215 3218
28. J. Calderaro, S. Rebouissou, L. de Koning, A. Masmoudi, A. Herault, and T. Dubois PI3K/AKT pathway activation in bladder carcinogenesis Int J Cancer 134 2013 1776 1784
29. M. Campone, T. Bachelot, M. Gnant, I. Deleu, H.S. Rugo, and B. Pistilli Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study Eur J Cancer 49 2013 2621 2632
30. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655 1657
31. D. Cappellen, Gil Diez, S. de Medina, D. Chopin, J.P. Thiery, and F. Radvanyi Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder Oncogene 14 1997 3059 3066
32. N. Carayol, E. Vakana, A. Sassano, S. Kaur, D.J. Goussetis, and H. Glaser Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells Proc Natl Acad Sci U S A 107 2010 12469 12474
33. J.S. Carew, K.R. Kelly, and S.T. Nawrocki Mechanisms of mTOR inhibitor resistance in cancer therapy Target Oncol 6 2011 17 27
34. C.L. Carpenter, K.R. Auger, M. Chanudhuri, M. Yoakim, B. Schaffhausen, and S. Shoelson Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit J Biol Chem 268 1993 9478 9483
35. J.D. Carpten, A.L. Faber, C. Horn, G.P. Donoho, S.L. Briggs, and C.M. Robbins A transforming mutation in the pleckstrin homology domain of AKT1 in cancer Nature 448 2007 439 444 (Epub Jul 2004)
36. A. Carracedo, J. Baselga, and P.P. Pandolfi Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors Cell Cycle 7 2008 3805 3809 (Epub Dec 3822)
37. A. Carracedo, L. Ma, J. Teruya-Feldstein, F. Rojo, L. Salmena, and A. Alimonti Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J Clin Invest 118 2008 3065 3074 10.1172/JCI34739
38. M. Castillo-Martin, J. Domingo-Domenech, O. Karni-Schmidt, T. Matos, and C. Cordon-Cardo Molecular pathways of urothelial development and bladder tumorigenesis Urol Oncol 28 2010 401 408
39. N. Chalhoub, and S.J. Baker PTEN and the PI3-kinase pathway in cancer Annu Rev Pathol 4 2009 127 150 10.1146/annurev.pathol.1144.110807.092311
40. F. Chang, J.T. Lee, P.M. Navolanic, L.S. Steelman, J.G. Shelton, and W.L. Blalock Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy Leukemia 17 2003 590 603
41. S.P. Chawla, A.P. Staddon, L.H. Baker, S.M. Schuetze, A.W. Tolcher, and G.Z. D'Amato Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas J Clin Oncol 30 2012 78 84
42. C.B. Ching, and D.E. Hansel Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway Lab Investig 90 2010 1406 1414
43. E. Chiong, I.L. Lee, A. Dadbin, A.L. Sabichi, L. Harris, and D. Urbauer Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells Clin Cancer Res 17 2011 2863 2873
44. L.W. Chow, S.Y. Tung, T.Y. Ng, S.A. Im, M.H. Lee, and A.Y. Yip Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II-III invasive breast cancer: the OOTR-N001 study Expert Opin Investig Drugs 22 2013 299 307
45. I. Cordes, M. Kluth, D. Zygis, M. Rink, F. Chun, and C. Eichelberg PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer Histopathology 63 2013 670 677
46. K.D. Courtney, R.B. Corcoran, and J.A. Engelman The PI3K pathway as drug target in human cancer J Clin Oncol 28 2010 1075 1083
47. P.B. Crino, K.L. Nathanson, and E.P. Henske The tuberous sclerosis complex N Engl J Med 355 2006 1345 1356
48. H.C. Dan, M.J. Cooper, P.C. Cogswell, J.A. Duncan, J.P. Ting, and A.S. Baldwin Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK Genes Dev 22 2008 1490 1500 10.1101/gad.1662308
49. Z. Darzynkiewicz, H. Zhao, H.D. Halicka, J. Li, Y.S. Lee, and T.C. Hsieh In search of antiaging modalities: evaluation of mTOR- and ROS/DNA damage-signaling by cytometry Cytometry A 85 2014 386 399
50. B.R. Davies, H. Greenwood, P. Dudley, C. Crafter, D.H. Yu, and J. Zhang Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background Mol Cancer Ther 11 2012 873 887
51. P. De, N. Dey, B. Terakedis, P.L. Bergsagel, Z.H. Li, and D. Mahadevan An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo Cancer Chemother Pharmacol 71 2013 867 881
52. G.D. Demetri, S.P. Chawla, I. Ray-Coquard, A. Le Cesne, A.P. Staddon, and M.M. Milhem Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy J Clin Oncol 31 2013 2485 2492
53. K. Du, and M. Montminy CREB is a regulatory target for the protein kinase Akt/PKB J Biol Chem 273 1998 32377 32379
54. M. Duenas, M. Martinez-Fernandez, R. Garcia-Escudero, F. Villacampa, M. Marques, and C. Saiz-Ladera PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors Mol Carcinog 2013 2013 22125
55. D. Egan, J. Kim, R.J. Shaw, and K.L. Guan The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR Autophagy 7 2011 643 644 (Epub Jun 2011)
56. J.A. Engelman Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer 9 2009 550 562 10.1038/nrc2664
57. J.A. Engelman, J. Luo, and L.C. Cantley The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat Rev Genet 7 2006 606 619
58. H. Fajkovic, J.A. Halpern, E.K. Cha, A. Bahadori, T.F. Chromecki, and P.I. Karakiewicz Impact of gender on bladder cancer incidence, staging, and prognosis World J Urol 29 2011 457 463
59. B.L. Falcon, S. Barr, P.C. Gokhale, J. Chou, J. Fogarty, and P. Depeille Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors Cancer Res 71 2011 1573 1583
60. N. Fazio, D. Granberg, A. Grossman, S. Saletan, J. Klimovsky, and A. Panneerselvam Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study Chest 143 2013 955 962
61. G. Fechner, K. Classen, D. Schmidt, S. Hauser, and S.C. Muller Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer Urology 73 2009 665 668 10.1016/j.urology.2008.1009.1070 (discussion Epub 2008 Dec 1011)
62. R.I. Feldman, J.M. Wu, M.A. Polokoff, M.J. Kochanny, H. Dinter, and D. Zhu Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1 J Biol Chem 280 2005 19867 19874 (Epub 12005 Mar 19816)
63. E. Fokas, M. Yoshimura, R. Prevo, G. Higgins, W. Hackl, and S.M. Maira NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity Radiat Oncol 7 2012 7 48
64. D.N. Franz Everolimus for astrocytomas in tuberous sclerosis - author's reply Lancet 381 2013 (60837-60835)
65. M.A. Frias, C.C. Thoreen, J.D. Jaffe, W. Schroder, T. Sculley, and S.A. Carr mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s Curr Biol 16 2006 1865 1870 (Epub Aug 1817)
66. P. Furet, V. Guagnano, R.A. Fairhurst, P. Imbach-Weese, I. Bruce, and M. Knapp Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation Bioorg Med Chem Lett 23 2013 3741 3748
67. R.R. Furman, J.P. Sharman, S.E. Coutre, B.D. Cheson, J.M. Pagel, and P. Hillmen Idelalisib and rituximab in relapsed chronic lymphocytic leukemia N Engl J Med 370 2014 997 1007
68. T. Gao, F. Furnari, and A.C. Newton PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth Mol Cell 18 2005 13 24
69. J.M. Garcia-Martinez, and D.R. Alessi mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1) Biochem J 416 2008 375 385 10.1042/BJ20081668
70. H. Gerullis, C. Eimer, T.H. Ecke, E. Georgas, C. Freitas, and S. Kastenholz A phase II trial of temsirolimus in second-line metastatic urothelial cancer Med Oncol 29 2012 2870 2876
71. P.J. Goebell, and M.A. Knowles Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium Urol Oncol 28 2010 409 428
72. H.J. Groen, H. Sietsma, A. Vincent, M.M. Hochstenbag, J.W. van Putten, and A. van den Berg Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study J Clin Oncol 29 2011 4320 4326
73. Y. Gui, G. Guo, Y. Huang, X. Hu, A. Tang, and S. Gao Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder Nat Genet 43 2011 875 878
74. G. Guo, X. Sun, C. Chen, S. Wu, P. Huang, and Z. Li Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation Nat Genet 45 2013 1459 1463
75. Y. Guo, Y. Chekaluk, J. Zhang, J. Du, N.S. Gray, and C.L. Wu TSC1 involvement in bladder cancer: diverse effects and therapeutic implications J Pathol 230 2013 17 27
76. K. Hara, Y. Maruki, X. Long, K. Yoshino, N. Oshiro, and S. Hidayat Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action Cell 110 2002 177 189
77. L.S. Harrington, G.M. Findlay, A. Gray, T. Tolkacheva, S. Wigfield, and H. Rebholz The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins J Cell Biol 166 2004 213 223 (Epub Jul 2012)
78. N. Hay The Akt-mTOR tango and its relevance to cancer Cancer Cell 8 2005 179 183
79. T.P. Heffron, M. Berry, G. Castanedo, C. Chang, I. Chuckowree, and J. Dotson Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor Bioorg Med Chem Lett 20 2010 2408 2411
80. J. Heitman, N.R. Movva, and M.N. Hall Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast Science 253 1991 905 909
81. G. Hess, R. Herbrecht, J. Romaguera, G. Verhoef, M. Crump, and C. Gisselbrecht Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma J Clin Oncol 27 2009 3822 3829 10.1200/JCO.2008.3820.7977 (Epub Jul 3826)
82. B. Hoang, P. Frost, Y. Shi, E. Belanger, A. Benavides, and G. Pezeshkpour Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor Blood 116 2010 4560 4568
83. T.A. Hornberger, K.B. Sukhija, X.R. Wang, and S. Chien mTOR is the rapamycin-sensitive kinase that confers mechanically-induced phosphorylation of the hydrophobic motif site Thr(389) in p70(S6k) FEBS Lett 581 2007 4562 4566 (Epub Aug 4531)
84. H.Z. Huo, Z.Y. Zhou, B. Wang, J. Qin, W.Y. Liu, and Y. Gu Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014 Biochem Biophys Res Commun 443 2014 406 412
85. T.E. Hutson, B. Escudier, E. Esteban, G.A. Bjarnason, H.Y. Lim, and K.B. Pittman Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 32 2014 760 767
86. N.T. Ihle, R. Williams, S. Chow, W. Chew, M.I. Berggren, and G. Paine-Murrieta Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling Mol Cancer Ther 3 2004 763 772
87. K. Inoki, Y. Li, T. Xu, and K.L. Guan Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling Genes Dev 17 2003 1829 1834 (Epub Jul 1817)
88. K. Inoki, Y. Li, T. Zhu, J. Wu, and K.L. Guan TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling Nat Cell Biol 4 2002 648 657
89. K. Inoki, T. Zhu, and K.L. Guan TSC2 mediates cellular energy response to control cell growth and survival Cell 115 2003 577 590
90. G. Iyer, A.J. Hanrahan, M.I. Milowsky, H. Al-Ahmadie, S.N. Scott, and M. Janakiraman Genome sequencing identifies a basis for everolimus sensitivity Science 338 2012 221
91. G. Iyer, H. Al-Ahmadie, N. Schultz, A.J. Hanrahan, I. Ostrovnaya, and A.V. Balar Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer J Clin Oncol 31 2013 3133 3140
92. E. Jacinto, R. Loewith, A. Schmidt, S. Lin, M.A. Ruegg, and A. Hall Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive Nat Cell Biol 6 2004 1122 1128 (Epub Oct 1123)
93. N.D. James, M.R. Sydes, M.D. Mason, N.W. Clarke, J. Anderson, and D.P. Dearnaley Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial Lancet Oncol 13 2012 549 558
94. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90 10.3322/caac.20107 (Epub 22011 Feb 20104)
95. J. Kagan, J. Liu, J.D. Stein, S.S. Wagner, R. Babkowski, and B.H. Grossman Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer Oncogene 16 1998 909 913
96. A.F. Kantor, P. Hartge, R.N. Hoover, and J.F. Fraumeni Jr. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder Cancer Res 48 1988 3853 3855
97. R. Katso, K. Okkenhaug, K. Ahmadi, S. White, J. Timms, and M.D. Waterfield Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer Annu Rev Cell Dev Biol 17 2001 615 675
98. D.H. Kim, D.D. Sarbassov, S.M. Ali, J.E. King, R.R. Latek, and H. Erdjument-Bromage mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery Cell 110 2002 163 175
99. D.H. Kim, D.D. Sarbassov, S.M. Ali, R.R. Latek, K.V. Guntur, and H. Erdjument-Bromage GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR Mol Cell 11 2003 895 904
100. J. Kim, M. Kundu, B. Viollet, and K.L. Guan AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 Nat Cell Biol 13 2011 132 141
101. J.J. Kim Recent advances in treatment of advanced urothelial carcinoma Curr Urol Rep 13 2012 147 152
102. Z.A. Knight, B. Gonzalez, M.E. Feldman, E.R. Zunder, D.D. Goldenberg, and O. Williams A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling Cell 125 2006 733 747 (EpubApr 2027)
103. M.A. Knowles, T. Habuchi, W. Kennedy, and D. Cuthbert-Heavens Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder Cancer Res 63 2003 7652 7656
104. M.A. Knowles, F.M. Platt, R.L. Ross, and C.D. Hurst Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer Cancer Metastasis Rev 28 2009 305 316 10.1007/s10555-10009-19198-10553
105. P. Korkolopoulou, G. Levidou, E.A. Trigka, N. Prekete, M. Karlou, and I. Thymara A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma BJU Int 110 2012 29
106. J. Krawczyk, N. Keane, R. Swords, M. O'Dwyer, C.L. Freeman, and F.J. Giles Perifosine - a new option in treatment of acute myeloid leukemia? Expert Opin Investig Drugs 22 2013 1315 1327
107. D.W. Lamming, L. Ye, D.M. Sabatini, and J.A. Baur Rapalogs and mTOR inhibitors as anti-aging therapeutics J Clin Invest 123 2013 980 989
108. B.J. Lannutti, S.A. Meadows, S.E. Herman, A. Kashishian, B. Steiner, and A.J. Johnson CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 117 2011 591 594
109. J. Liang, J. Zubovitz, T. Petrocelli, R. Kotchetkov, M.K. Connor, and K. Han PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest Nat Med 8 2002 1153 1160 (Epub Sep 1116)
110. C.C. Lin, C.H. Hsu, Y.S. Pu, and N.J. Vogelzang Systemic therapy for metastatic urothelial carcinoma BJU Int 101 2008 795 803 (Epub 2007 Dec 2005)
111. J. Lin, D. Sampath, M.A. Nannini, B.B. Lee, M. Degtyarev, and J. Oeh Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models Clin Cancer Res 19 2013 1760 1772
112. D. Lindgren, G. Sjodahl, M. Lauss, J. Staaf, G. Chebil, and K. Lovgren Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma PLoS ONE 7 2012 e38863
113. N. Liu, B.R. Rowley, C.O. Bull, C. Schneider, A. Haegebarth, and C.A. Schatz BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models Mol Cancer Ther 12 2013 2319 2330
114. P. Liu, H. Cheng, T.M. Roberts, and J.J. Zhao Targeting the phosphoinositide 3-kinase pathway in cancer Nat Rev Drug Discov 8 2009 627 644 10.1038/nrd2926
115. Q. Liu, J. Wang, S.A. Kang, C.C. Thoreen, W. Hur, and T. Ahmed Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer J Med Chem 54 2011 1473 1480
116. Q. Liu, C. Xu, S. Kirubakaran, X. Zhang, W. Hur, and Y. Liu Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR Cancer Res 73 2013 2574 2586
117. X. Liu, Y. Shi, K.W. Woods, P. Hessler, P. Kroeger, and J. Wilsbacher Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression Neoplasia 10 2008 828 837
118. E. Lopez-Knowles, S. Hernandez, N. Malats, M. Kogevinas, J. Lloreta, and A. Carrato PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors Cancer Res 66 2006 7401 7404
119. Y. Luo, A.R. Shoemaker, X. Liu, K.W. Woods, S.A. Thomas, and R. de Jong Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo Mol Cancer Ther 4 2005 977 986
120. L. Ma, Z. Chen, H. Erdjument-Bromage, P. Tempst, and P.P. Pandolfi Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis Cell 121 2005 179 193
121. D. Mahalingam, E.C. Medina, J.A. Esquivel II, C.M. Espitia, S. Smith, and K. Oberheu Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels Clin Cancer Res 16 2010 141 153
122. S.M. Maira, S. Pecchi, A. Huang, M. Burger, M. Knapp, and D. Sterker Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor Mol Cancer Ther 11 2012 317 328
123. R. Mallon, I. Hollander, L. Feldberg, J. Lucas, V. Soloveva, and A. Venkatesan Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor Mol Cancer Ther 9 2010 976 984
124. M.C. Manara, G. Nicoletti, D. Zambelli, S. Ventura, C. Guerzoni, and L. Landuzzi NVP-BEZ235 as a new therapeutic option for sarcomas Clin Cancer Res 16 2010 530 540
125. B.D. Manning, and L.C. Cantley Rheb fills a GAP between TSC and TOR Trends Biochem Sci 28 2003 573 576
126. J.J. Mansure, R. Nassim, S. Chevalier, J. Rocha, E. Scarlata, and W. Kassouf Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer Cancer Biol Ther 8 2009 2339 2347 (Epub Dec 2332)
127. P.M. Marcus, R.B. Hayes, P. Vineis, M. Garcia-Closas, N.E. Caporaso, and H. Autrup Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction Cancer Epidemiol Biomarkers Prev 9 2000 461 467
128. P.M. Marcus, P. Vineis, and N. Rothman NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population Pharmacogenetics 10 2000 115 122
129. B. Markman, R. Dienstmann, and J. Tabernero Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs Oncotarget 1 2010 530 543
130. B. Markman, J. Tabernero, I. Krop, G.I. Shapiro, L. Siu, and L.C. Chen Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors Ann Oncol 23 2012 2399 2408
131. J. Martin, J. Masri, A. Bernath, R.N. Nishimura, and J. Gera Hsp70 associates with Rictor and is required for mTORC2 formation and activity Biochem Biophys Res Commun 372 2008 578 583 10.1016/j.bbrc.2008.1005.1086 (Epub May 1027)
132. R. Maruyama, S. Toyooka, K.O. Toyooka, K. Harada, A.K. Virmani, and S. Zochbauer-Muller Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features Cancer Res 61 2001 8659 8663
133. M. Matic, T. Pekmezovic, T. Djukic, J. Mimic-Oka, D. Dragicevic, and B. Krivic GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study Urol Oncol 31 2013 1184 1192
134. J.A. McCubrey, L.S. Steelman, W.H. Chappell, S.L. Abrams, R.A. Franklin, and G. Montalto Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance Oncotarget 3 2012 1068 1111
135. J.A. McCubrey, L.S. Steelman, W.H. Chappell, S.L. Abrams, G. Montalto, and M. Cervello Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response Oncotarget 3 2012 954 987
136. M.C. Mendoza, E.E. Er, and J. Blenis The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation Trends Biochem Sci 36 2011 320 328
137. P. Mhawech-Fauceglia, R.T. Cheney, and J. Schwaller Genetic alterations in urothelial bladder carcinoma: an updated review Cancer 106 2006 1205 1216
138. M.I. Milowsky, G. Iyer, A.M. Regazzi, H. Al-Ahmadie, S.R. Gerst, and I. Ostrovnaya Phase II study of everolimus in metastatic urothelial cancer BJU Int 112 2013 462 470
139. O.K. Mirzoeva, B. Hann, Y.K. Hom, J. Debnath, D. Aftab, and K. Shokat Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma J Mol Med 89 2011 877 889
140. R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, and S. Bracarda Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
141. P. Munster, R. van der Noll, E. Voest, J. Specht, T.L. Werner, and E.C. Dees PI3K kinase inhibitor GSK2126458 (GSK458): clinical activity in select patient (pt) populations defined by predictive markers (study P3K112826) Ann Oncol 23 2012 (abstract 4420)
142. A. Najafov, E.M. Sommer, J.M. Axten, M.P. Deyoung, and D.R. Alessi Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1 Biochem J 433 2011 357 369
143. F. Nazio, F. Strappazzon, M. Antonioli, P. Bielli, V. Cianfanelli, and M. Bordi mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6 Nat Cell Biol 15 2013 406 416
144. M.S. Neshat, I.K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, and R. Petersen Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci U S A 98 2001 10314 10319 (Epub 12001 Aug 10314)
145. T.C.G.A.R. Network Comprehensive molecular characterization of urothelial bladder carcinoma Nature 2014 2014
146. W.J. Oh, and E. Jacinto mTOR complex 2 signaling and functions Cell Cycle 10 2011 2305 2316 (Epub Jul 2315)
147. W.J. Oh, C.C. Wu, S.J. Kim, V. Facchinetti, L.A. Julien, and M. Finlan mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide EMBO J 29 2010 3939 3951
148. A. Ohtsu, J.A. Ajani, Y.X. Bai, Y.J. Bang, H.C. Chung, and H.M. Pan Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study J Clin Oncol 31 2013 3935 3943
149. E. Okajima, T. Hiramatsu, K. Iriya, M. Ijuin, and S. Matsushima Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine Urol Res 3 1975 73 79
150. O.N. Ozes, L.D. Mayo, J.A. Gustin, S.R. Pfeffer, L.M. Pfeffer, and D.B. Donner NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase Nature 401 1999 82 85
151. A. Pause, G.J. Belsham, A.C. Gingras, O. Donze, T.A. Lin, and J.C. Lawrence Jr. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function Nature 371 1994 762 767
152. M.E. Pavel, J.D. Hainsworth, E. Baudin, M. Peeters, D. Horsch, and R.E. Winkler Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Lancet 378 2011 2005 2012
153. T.R. Peterson, M. Laplante, C.C. Thoreen, Y. Sancak, S.A. Kang, and W.M. Kuehl DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival Cell 137 2009 873 886 10.1016/j.cell.2009.1003.1046 (Epub May 1014)
154. K.G. Pike, K. Malagu, M.G. Hummersone, K.A. Menear, H.M. Duggan, and S. Gomez Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014 Bioorg Med Chem Lett 23 2013 1212 1216
155. F.M. Platt, C.D. Hurst, C.F. Taylor, W.M. Gregory, P. Harnden, and M.A. Knowles Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer Clin Cancer Res 15 2009 6008 6017 10.1158/1078-0432.CCR-6009-0898 (Epub 2009 Sep 6029)
156. M. Ploeg, K.K. Aben, and L.A. Kiemeney The present and future burden of urinary bladder cancer in the world World J Urol 27 2009 289 293 10.1007/s00345-00009-00383-00343 (Epub 02009 Feb 00315)
157. K. Podsypanina, R.T. Lee, C. Politis, I. Hennessy, A. Crane, and J. Puc An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice Proc Natl Acad Sci U S A 98 2001 10320 10325 (Epub 12001 Aug 10314)
158. M.G. Ponzo, and M. Park The Met receptor tyrosine kinase and basal breast cancer Cell Cycle 9 2010 1043 1050
159. H. Populo, J.M. Lopes, and P. Soares The mTOR signalling pathway in human cancer Int J Mol Sci 13 2012 1886 1918
160. G. Prasad, T. Sottero, X. Yang, S. Mueller, C.D. James, and W.A. Weiss Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide Neurol Oncol 13 2011 384 392
161. E. Prat, M. Bernues, M.R. Caballin, J. Egozcue, A. Gelabert, and R. Miro Detection of chromosomal imbalances in papillary bladder tumors by comparative genomic hybridization Urology 57 2001 986 992
162. R. Prevo, E. Deutsch, O. Sampson, J. Diplexcito, K. Cengel, and J. Harper Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity Cancer Res 68 2008 5915 5923 10.1158/0008-5472.CAN-5908-0757
163. L.S. Pymar, F.M. Platt, J.M. Askham, E.E. Morrison, and M.A. Knowles Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms Hum Mol Genet 17 2008 2006 2017 10.1093/hmg/ddn2098 (Epub Apr 2007)
164. F.I. Raynaud, S. Eccles, P.A. Clarke, A. Hayes, B. Nutley, and S. Alix Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases Cancer Res 67 2007 5840 5850
165. N. Rhodes, D.A. Heerding, D.R. Duckett, D.J. Eberwein, V.B. Knick, and T.J. Lansing Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity Cancer Res 68 2008 2366 2374 10.1158/0008-5472.CAN-2307-5783
166. J. Richter, U. Wagner, P. Schraml, R. Maurer, G. Alund, and H. Knonagel Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer Cancer Res 59 1999 5687 5691
167. B.I. Rini, J. Bellmunt, J. Clancy, K. Wang, A.G. Niethammer, and S. Hariharan Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial J Clin Oncol 32 2014 752 759
168. J. Rodon, I. Brana, L.L. Siu, M.J. De Jonge, N. Homji, and D. Mills Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors Investig New Drugs 2014 2014 21
169. J. Rodon, R. Dienstmann, V. Serra, and J. Tabernero Development of PI3K inhibitors: lessons learned from early clinical trials Nat Rev Clin Oncol 10 2013 143 153
170. R.L. Ross, J.M. Askham, and M.A. Knowles PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs Oncogene 32 2013 768 776
171. R.L. Ross, J.E. Burns, C.F. Taylor, P. Mellor, D.H. Anderson, and M.A. Knowles Identification of mutations in distinct regions of p85 alpha in urothelial cancer PLoS ONE 8 2013 2013
172. Y. Sancak, C.C. Thoreen, T.R. Peterson, R.A. Lindquist, S.A. Kang, and E. Spooner PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase Mol Cell 25 2007 903 915
173. D.D. Sarbassov, S.M. Ali, D.H. Kim, D.A. Guertin, R.R. Latek, and H. Erdjument-Bromage Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton Curr Biol 14 2004 1296 1302
174. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
175. T. Sato, A. Nakashima, L. Guo, and F. Tamanoi Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein J Biol Chem 284 2009 12783 12791 10.11074/jbc.M809207200 (Epub 809202009 Mar 809207219)
176. E. Seront, A. Pinto, C. Bouzin, L. Bertrand, J.P. Machiels, and O. Feron PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation Br J Cancer 109 2013 1586 1592
177. E. Seront, S. Rottey, B. Sautois, J. Kerger, L.A. D'Hondt, and V. Verschaeve Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers Ann Oncol 23 2012 2663 2670 (Epub 2012 Apr 2663)
178. V. Serra, B. Markman, M. Scaltriti, P.J. Eichhorn, V. Valero, and M. Guzman NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations Cancer Res 68 2008 8022 8030 10.1158/0008-5472.CAN-8008-1385
179. V. Sgnaolin, T.C. Pereira, M.R. Bogo, R. Zanin, A.M. Battastini, and F.B. Morrone Functional and molecular characterization of kinin B1 and B 2 receptors in human bladder cancer: implication of the PI3Kgamma pathway Investig New Drugs 31 2013 812 822
180. G.I. Shapiro, J. Rodon, C. Bedell, E.L. Kwak, J. Baselga, and I. Brana Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors Clin Cancer Res 20 2014 233 245
181. R.J. Shaw, and L.C. Cantley Ras, PI(3)K and mTOR signalling controls tumour cell growth Nature 441 2006 424 430
182. Y. Shi, J. Gera, L. Hu, J.H. Hsu, R. Bookstein, and W. Li Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779 Cancer Res 62 2002 5027 5034
183. T. Shibata, T. Ohta, K.I. Tong, A. Kokubu, R. Odogawa, and K. Tsuta Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy Proc Natl Acad Sci U S A 105 2008 13568 13573 10.11073/pnas.0806268105 (Epub 0806262008 Aug 0806268129)
184. R.P. Shugg, A. Thomson, N. Tanabe, A. Kashishian, B.H. Steiner, and K.D. Puri Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption J Biol Chem 288 2013 35346 35357
185. R. Simon, H. Burger, A. Semjonow, L. Hertle, H.J. Terpe, and W. Bocker Patterns of chromosomal imbalances in muscle invasive bladder cancer Int J Oncol 17 2000 1025 1029
186. T.T. Sio, J. Ko, V.K. Gudena, N. Verma, and U.B. Chaudhary Chemotherapeutic and targeted biological agents for metastatic bladder cancer: a comprehensive review Int J Urol 2014 2014 12407
187. G. Sjodahl, M. Lauss, S. Gudjonsson, F. Liedberg, C. Hallden, and G. Chebil A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1 PLoS ONE 6 2011 0018583
188. A.S. Skopelitou, G. Gloustianou, M. Bai, and K. Huebner FHIT gene expression in human urinary bladder transitional cell carcinomas In Vivo 15 2001 169 173
189. J.A. Smith Jr., R.F. Labasky, A.T. Cockett, J.A. Fracchia, J.E. Montie, and R.G. Rowland Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association J Urol 162 1999 1697 1701
190. D.A. Solomon, J.S. Kim, J. Bondaruk, S.F. Shariat, Z.F. Wang, and A.G. Elkahloun Frequent truncating mutations of STAG2 in bladder cancer Nat Genet 45 2013 1428 1430
191. L.S. Steelman, P.M. Navolanic, M.L. Sokolosky, J.R. Taylor, B.D. Lehmann, and W.H. Chappell Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors Oncogene 27 2008 4086 4095 10.1038/onc.2008.4049 (Epub Mar 4010)
192. L.S. Steelman, K.M. Stadelman, W.H. Chappell, S. Horn, J. Basecke, and M. Cervello Akt as a therapeutic target in cancer Expert Opin Ther Targets 12 2008 1139 1165 10.1517/14728222.14728212.14728229.14721139
193. A. Stenzl, N.C. Cowan, M. De Santis, M.A. Kuczyk, A.S. Merseburger, and M.J. Ribal Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur Urol 59 2011 1009 1018
194. D. Stokoe, L.R. Stephens, T. Copeland, P.R. Gaffney, C.B. Reese, and G.F. Painter Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B Science 277 1997 567 570
195. T. Tamguney, C. Zhang, D. Fiedler, K. Shokat, and D. Stokoe Analysis of 3-phosphoinositide-dependent kinase-1 signaling and function in ES cells Exp Cell Res 314 2008 2299 2312 10.1016/j.yexcr.2008.2204.2006 (Epub Apr 2223)
196. D.S. Tan, H. Dumez, D. Olmos, S.K. Sandhu, A. Hoeben, and A.W. Stephens First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma J Clin Oncol 28 2010 (Suppl.; abstr 3006)
197. H. Tanaka, M. Yoshida, H. Tanimura, T. Fujii, K. Sakata, and Y. Tachibana The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations Clin Cancer Res 17 2011 3272 3281
198. P.L. Tazzari, A. Cappellini, F. Ricci, C. Evangelisti, V. Papa, and T. Grafone Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts Leukemia 21 2007 427 438 (Epub Jan 2011)
199. The Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma Nature 2014 2014
200. C.C. Thoreen, S.A. Kang, J.W. Chang, Q. Liu, J. Zhang, and Y. Gao An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 J Biol Chem 284 2009 8023 8032 10.1074/jbc.M900301200 (Epub 900302009 Jan 900301215)
201. H. Tigli, D. Seven, M. Tunc, O. Sanli, S. Basaran, and T. Ulutin LKB1 mutations and their correlation with LKB1 and Rheb expression in bladder cancer Mol Carcinog 52 2013 660 665
202. O. Tredan, I. Treilleux, Q. Wang, N. Gane, D. Pissaloux, and N. Bonnin Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study Target Oncol 8 2013 243 251
203. A.M. Venkatesan, Z. Chen, O. dos Santos, C. Dehnhardt, E.D. Santos, and S. Ayral-Kaloustian PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor Bioorg Med Chem Lett 20 2010 5869 5873
204. H. von der Maase, L. Sengelov, J.T. Roberts, S. Ricci, L. Dogliotti, and T. Oliver Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602 4608
205. J.J. Wallin, K.A. Edgar, J. Guan, M. Berry, W.W. Prior, and L. Lee GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway Mol Cancer Ther 10 2011 2426 2436
206. D.S. Wang, K. Rieger-Christ, J.M. Latini, A. Moinzadeh, J. Stoffel, and J.A. Pezza Molecular analysis of PTEN and MXI1 in primary bladder carcinoma Int J Cancer 88 2000 620 625
207. E. Weisberg, L. Banerji, R.D. Wright, R. Barrett, A. Ray, and D. Moreno Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells Blood 111 2008 3723 3734 10.1182/blood-2007-3709-114454 (Epub 112008 Jan 114459)
208. N.W. West, A. Garcia-Vargas, C.E. Chalfant, and M.A. Park OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2 BMC Cancer 13 2013 1471 2407
209. M.A. Westhoff, J.A. Kandenwein, S. Karl, S.H. Vellanki, V. Braun, and A. Eramo The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair Oncogene 28 2009 3586 3596 10.1038/onc.2009.3215 (Epub Jul 3527)
210. S.V. Williams, C.D. Hurst, and M.A. Knowles Oncogenic FGFR3 gene fusions in bladder cancer Hum Mol Genet 22 2013 795 803
211. J.A. Witjes, E. Comperat, N.C. Cowan, M. De Santis, G. Gakis, and T. Lebret EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines Eur Urol 65 2014 778 792
212. A.C. Wolff, A.A. Lazar, I. Bondarenko, A.M. Garin, S. Brincat, and L. Chow Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer J Clin Oncol 31 2013 195 202
213. Y.M. Wu, F. Su, S. Kalyana-Sundaram, N. Khazanov, B. Ateeq, and X. Cao Identification of targetable FGFR gene fusions in diverse cancers Cancer Discov 3 2013 636 647
214. S. Yaguchi, Y. Fukui, I. Koshimizu, H. Yoshimi, T. Matsuno, and H. Gouda Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor J Natl Cancer Inst 98 2006 545 556
215. H. Yang, D.G. Rudge, J.D. Koos, B. Vaidialingam, H.J. Yang, and N.P. Pavletich mTOR kinase structure, mechanism and regulation Nature 497 2013 217 223
216. D.S. Yee, N.M. Ishill, W.T. Lowrance, H.W. Herr, and E.B. Elkin Ethnic differences in bladder cancer survival Urology 78 2011 544 549
217. H. You, M. Pellegrini, K. Tsuchihara, K. Yamamoto, G. Hacker, and M. Erlacher FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal J Exp Med 203 2006 1657 1663 (Epub 2006 Jun 1626)
218. K. Yu, C. Shi, L. Toral-Barza, J. Lucas, B. Shor, and J.E. Kim Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2 Cancer Res 70 2010 621 631
219. K. Yu, L. Toral-Barza, C. Shi, W.G. Zhang, J. Lucas, and B. Shor Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin Cancer Res 69 2009 6232 6240 10.1158/0008-5472.CAN-6209-0299 (Epub Jul 6237)
220. J. Yuan, P.P. Mehta, M.J. Yin, S. Sun, A. Zou, and J. Chen PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity Mol Cancer Ther 10 2011 2189 2199
221. Z. Zeng, I.J. Samudio, W. Zhang, Z. Estrov, H. Pelicano, and D. Harris Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia Cancer Res 66 2006 3737 3746
222. Z. Zeng, D. Sarbassov dos, I.J. Samudio, K.W. Yee, M.F. Munsell, and C. Ellen Jackson Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML Blood 109 2007 3509 3512 (Epub 2006 Dec 3519)
223. H. Zhou, and S. Huang Role of mTOR signaling in tumor cell motility, invasion and metastasis Curr Protein Pept Sci 12 2011 30 42
224. J. Zhu, J.W. Huang, P.H. Tseng, Y.T. Yang, J. Fowble, and C.W. Shiau From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors Cancer Res 64 2004 4309 4318
225. R. Zoncu, A. Efeyan, and D.M. Sabatini mTOR: from growth signal integration to cancer, diabetes and ageing Nat Rev Mol Cell Biol 12 2011 21 35
226. Z.Q. Zou, L.N. Zhang, F. Wang, J. Bellenger, Y.Z. Shen, and X.H. Zhang The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells Mol Med Rep 5 2012 503 508 10.3892/mmr.2011.3682 (Epub 2011 Nov 3816)